Drug Groups

approved

Description

Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics. [PubChem]

Indication

For the treatment of polymicrobial infections.

Pharmacology

Piperacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Piperacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Piperacillin results from the inhibition of cell wall synthesis and is mediated through Piperacillin binding to penicillin binding proteins (PBPs). Piperacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.

Affected Organisms

Biotransformation

Largely not metabolized.

Absorption

Not absorbed following oral administration.

Half Life

36-72 minutes

Elimination

As with other penicillins, PIPRACIL is eliminated primarily by glomerular filtration and tubular secretion; it is excreted rapidly as unchanged drug in high concentrations in the urine. Because PIPRACIL is excreted by the biliary route as well as by the renal route, it can be used safely in appropriate dosage in patients with severely restricted kidney function.

Distribution

* 101 mL/kg [intravenous administration of 50 mg/kg (5-minute infusion) in neonates]

Clearance

* 32?-?41 mL/min/1.73?m2
* 124?-?160 mL/min/1.73?m2 [older pediatric patients]

References

External Links